AstraZeneca Sees Strong Oncology-Driven Japan Growth
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca sees “very, very good growth” for its Japanese business in the mid-term, driven by newer already launched drugs, a full local pipeline and an expected two product launches a year over the period to 2020.